Physician profile
John P Thalken
NPI 1912007212
$1,381.54
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $174 · 2021: $310 · 2022: $284 · 2023: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $208.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $267.63 | 2019-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $208.58 | 2019-2023 | Breztri, Farxiga |
| Lilly USA, LLC | $150.57 | 2019-2023 | Mounjaro, Baqsimi, Emgality |
| Sanofi-Aventis U.S. LLC | $149.15 | 2019-2022 | |
| Amgen INC. | $139.10 | 2019-2023 | Prolia, Evenity |
| Novo Nordisk INC | $95.45 | 2019-2023 | Rybelsus, Ozempic |
| Allergan, INC. | $78.97 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $76.69 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $63.90 | 2019-2021 | |
| Abbvie INC. | $32.16 | 2021-2022 | |
| Abbott Laboratories | $24.47 | 2022 | |
| Pfizer INC. | $23.24 | 2019 | |
| Optinose US, INC. | $17.19 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.10 | 2019 | |
| Ethicon US, LLC | $14.40 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $13.42 | 2021 | |
| Astellas Pharma US INC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thalken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.